Navigation Links
Gene Mutations Causing Rett Syndrome Occur in Both Sexes

Recent research has revealed that gene mutations that are responsible for about seventy to eighty percent of cases of Rett syndrome (RTT) in females are not always lethal// in males prior to birth. This has refuted previous assumptions, and can occur sporadically in infant males without a family history of the disorder. A study published in the journal Neurology reports four sporadic occurrences of MECP2 gene mutations in infant males with progressive encephalopathy. RTT is an X-linked neurodevelopmental disorder that is caused by mutations in the MECP2 gene and is characterized by stagnation of development followed by regression.

In an international collaboration, researchers from the United States and Australia identified and evaluated four non-familial, sporadic occurrences of MECP2 gene mutations. Prior to this study, the majority of reported males with MECP2 mutations had a family history of RTT. Based on the results of this study, MECP2 abnormalities should be evaluated in young infant males who develop progressive encephalopathy including respiratory insufficiency, microcephaly, abnormal muscle tone and various movement disorders, as mutations to the gene may be the source of the infant’s neurological problems.

"Boys born to families with a history of Rett syndrome are examined very closely for MECP2 mutations, but beyond these families, physicians usually do not test for mutations to the gene," said Walter E. Kaufmann, M.D., study author and research scientist at the Kennedy Krieger Institute in Baltimore. "Infant males with progressive encephalopathy may go undiagnosed because the prevailing assumption is that males with these mutations die before they are born. We've found that this is not the case, and encourage neonatologists and pediatricians to consider MECP2 as a possible cause of severe neurological abnormalities."

All four newly identified cases exhibited common features, including: moderate or severe early postna tal progressive encephalopathy; unexplained central hypoventilation or respiratory insufficiency; abnormal movements; intractable seizures and abnormal tone. Three of the four cases had definitely pathogenic mutations and the fourth was potentially pathogenic. Acute observations and knowledge of the clinical picture of RTT prompted suspicion of MECP2 mutations in the four newly reported cases.

"While the findings of this study represent an important step forward in learning more about MECP2 mutations in infant males, many questions still remain regarding the role of the gene and its contribution to the encephalopathy of Rett syndrome," said Dr. Gary Goldstein, President and CEO of the Kennedy Krieger Institute. "To help answer these and other questions regarding RTT, Kennedy Krieger has played a leading role in organizing an international consortium of scientists from every major Rett center around the world to conduct clinical studies on the diagnosis and treatment of the disorder."

The consortium, called 'RettSearch,' will provide a forum for scientists to combine research efforts and share results from around the world. With only 15 cases of MECP2 mutations in infant males currently identified worldwide, researchers' observations are limited. Through the 'RettSearch' network, which is being coordinated by Dr. Kaufmann, scientists from Kennedy Krieger and other member institutions hope to identify additional cases and conduct multi-center trials with both males and females with MECP2 mutations and RTT.

About Rett Syndrome Rett Syndrome (RTT) is a neurological disorder often misdiagnosed as autism, cerebral palsy or non-specified developmental delay caused by a defective regulatory MECP2 gene found on the X chromosome. The disorder is seen almost exclusively in females. Unlike females, who have two X-chromosomes, males have an X and a Y chromosome. Because males lack a "backup" copy of the X chromosome that can compensate for a d efective one, mutations in MECP2 are often lethal to the male fetus. This is why RTT is found overwhelmingly in females. RTT occurs in a variety of racial and ethnic groups worldwide and is now known to occur in 1:10,000 to 1:23,000 female births, but incidence may be far greater as new genetic evidence is discovered.

Development appears normal until 6-18 months of age, followed by loss of acquired speech and hand skills, slowing of head growth and development of stereotyped repetitive hand movements such as hand washing, hand wringing, hand tapping, hand clapping and hand mouthing. Stereotyped hand movements may change over time and additional problems may include seizures, breathing irregularities (hyperventilation and apnea), teeth grinding and curvature of the spine (scoliosis).

About the Kennedy Krieger Institute Internationally recognized for improving the lives of children and adolescents with disorders and injuries of the brain and spinal cord, the Kennedy Krieger Institute in Baltimore, MD serves more than 12,000 individuals each year through inpatient and outpatient clinics, home and community services and school-based programs. Kennedy Krieger provides a wide range of services for children with developmental concerns mild to severe, and is home to a team of investigators who are contributing to the understanding of how disorders develop while pioneering new interventions and earlier diagnosis.

Source: Eurekalert

Related medicine news :

1. Stem Cells Have Few Mutations
2. Mutations in NOTCH1 cause an early developmental defect in the aortic valve
3. Developing Countries Undertake Cataloguing of Human Mutations
4. New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer
5. Scinetists Alert to Onset of Pandemic through Bird flu Mutations to Humans
6. Certain Gene Mutations Numbs Pain
7. Genetic Mutations - Key to Autism ?
8. Cancer Gene Mutations Not Uncommon in General Population
9. Computer Tool Helps Pinpoint Risky Gene Mutations
10. More Mutations Of Gene That Cause Skin Disorders And Asthma Discovered
11. Gene Mutations Behind Fidgety Kids: German Scientists
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... ... has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare ... IT Healthcare was recognized as a finalist in the category of Digital Solutions ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... 2015 , ... PartnerTech , a leader in high-tech ... 2008. Gary Bruce, President of PartnerTech North America, currently serves as Director for ... of time in Sweden since joining PartnerTech based in Malmo, Sweden. He has ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of ... to date. , The order will be from the China Disabled Persons’ Federation, ... System is an effective solution for children and adults suffering from severe and ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... India , December 1, 2015 ... market research report "Immunotherapy Drugs Market by Type of Drug ... Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast ... is poised to reach USD 73,529.2 Million by 2020 from ... from 2015 to 2020. Browse 37 ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... 2015 During the recent 2015 Transcatheter ... Francisco, CA , Medinol Ltd. continued to ... During a satellite symposium, "The BioNIR eDES: The ... Restenosis", a renowned physician panel discussed the key ... Coronary Stent System and the Medinol eDES Coronary ...
Breaking Medicine Technology: